Kever Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 2.00 Cr
- Company Age 34 Year, 10 Months
- Last Filing with ROC 31 Mar 2008
- Open Charges ₹ 60.00 Cr
- Satisfied Charges ₹ 5.50 Cr
About Kever Pharma
Kever Pharma Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 March 1990 and has a history of 34 years and ten months. Its registered office is in Bidar, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2008. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹60.00 Cr. The company has closed loans amounting to ₹5.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Syam Suri and Prameela Kalavakolanu serve as directors at the Company.
Company Details
-
Location
Bidar, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239KA1990PTC010804
-
Company No.
010804
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Mar 1990
-
Date of AGM
29 Sep 2008
-
Date of Balance Sheet
31 Mar 2008
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Kever Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Syam Suri
|
Director | 11-May-2005 | Current |
|
Prameela Kalavakolanu
|
Director | 07-Mar-1990 | Current |
Financial Performance of Kever Pharma.
Enhance accessibility to Kever Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kever Pharma?
Unlock access to Kever Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹60.00 Cr
₹5.50 Cr
Charges Breakdown by Lending Institutions
- Ifci Limited : 60.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Feb 2010 | Ifci Limited | ₹60.00 Cr | Open |
| 03 Aug 2005 | Syndicate Bank | ₹5.50 Cr | Satisfied |
How Many Employees Work at Kever Pharma?
Unlock and access historical data on people associated with Kever Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kever Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kever Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.